ImmuCell Q3 revenue surges; swings to profit
ICCC•ImmuCell's third-quarter revenue rose 46% year over year to $8.04 million, and it swung to net income of $953,000 from a year-ago loss. Earnings were $0.10 per share.
1. Quarterly results
ImmuCell said third-quarter revenue rose 46% year over year to $8.04 million, while net income was $953,000, or $0.10 per share. Distributor out-the-door volume increased 18% year over year, with growth across sales territories and product lines.
2. Drivers and outlook
Revenue growth benefited from the absence of distributor restocking headwinds that had hurt sales in the year-earlier quarter. Gross margin increased on higher pricing and improved manufacturing execution, partly offset by product development expenses shifted to cost of goods sold. The company is investing in capacity expansion and colostrum sourcing, expects to sign a new $3 million line of credit in the fourth quarter of 2026, and sees favorable inventory levels heading into peak season.
